Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

Blood

Volumn 112, Issue 8, 2008, Pages 3130-3134

  Sanz, Miguel A ^a   Montesinos, Pau ^a,b   Vellenga, Edo ^c   Rayón, Consuelo ^d   De La Serna, Javier ^e   Parody, Ricardo ^f   Bergua, Juan M ^g   León, Angel ^h   Negri, Silvia ⁱ   González, Marcos ^j   Rivas, Concha ^k   Esteve, Jordi ^l   Milone, Gustavo ^m   González, José D ⁿ   Amutio, Elena ^o   Brunet, Salut ^p   Garcia Larana J ^q   Colomer, Dolors ^l   Calasanz, María J ^r   Chillón, Carmen ^j   Barragán, Eva ^a   Bolufer, Pascual ^a   Lowenberg, Bob ^s   more..

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^h HOSPITAL DE JEREZ   (Spain)

ⁱ HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^j HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^l HOSPITAL CLÍNIC   (Spain)

^m Fundacion para Combatir La Leucemia   (Argentina)

ⁿ HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^o HOSPITAL DE CRUCES   (Spain)

^p HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^q HOSPITAL RAMÓN Y CAJAL   (Spain)

^r UNIVERSITY OF NAVARRA   (Spain)

^s ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; COHORT ANALYSIS; MIDDLE AGED; RECURRENT DISEASE;

ADOLESCENT; ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME; TRETINOIN;

EID: 54049087434     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-159632     Document Type: Article

References (13)

1. Sanz MA. Treatment of acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program. 2006;147-155.
2. Sanz MA, Martín G, González M, et al. Riskadapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA Group. Blood. 2004;103:1237-1243.
3. Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96: 1247-1253.
4. Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARapositive acute promyelocytic leukemia. Blood. 1999;94:3015-3021.
5. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
6. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
7. Gray RJ. Aclass of K-sample test for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
8. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risk failure time data? Stat Med. 1993;12: 737-751.
9. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
10. de la Serna J, Montesinos P, Vellenga E. et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111:3395-3402.
11. Shuster JJ, Wacker P, Pullen J, et al. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol. 1998;16:2854-2863.
12. Pui CH, Boyett JM, Railing MV, et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol. 1999;17:818-824.
13. De Botton S, Sanz MA, Chevret S, et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia. 2006;20:35-41.